Evaluating the effectiveness of lifestyle therapy versus standard psychotherapy for reducing depression in adults with COVID-19 related distress: The CALM trial
- Funded by National Health and Medical Research Council (NHMRC)
- Total publications:0 publications
Grant number: GA133346
Grant search
Key facts
Disease
COVID-19Start & end year
20202022Known Financial Commitments (USD)
$628,564.78Funder
National Health and Medical Research Council (NHMRC)Principal Investigator
N/A
Research Location
AustraliaLead Research Institution
Deakin UniversityResearch Priority Alignment
N/A
Research Category
Secondary impacts of disease, response & control measures
Research Subcategory
Indirect health impacts
Special Interest Tags
Digital Health
Study Type
Clinical
Clinical Trial Details
Not applicable
Broad Policy Alignment
Pending
Age Group
Unspecified
Vulnerable Population
Other
Occupations of Interest
Unspecified
Abstract
The mental health of Australians has deteriorated since the COVID-19 outbreak. Our data show almost 1 in 2 Australians experienced depression during lockdown. CALM is an 8-week group-based, telehealth, lifestyle program for those with elevated psychological distress. It is delivered in Victoria as part of a partnership between Deakin University and Barwon Health's Mental Health, Drug and Alcohol Services. We anticipate CALM will be as effective and cost-effective as therapy for reducing depression.